Entera Bio Ltd. ENTXW 深 沪
等待开盘 08-25 09:30:00 美东时间
0.0012
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0012
- 总市值 2.85万
- 52周最高 0.328
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.00
- 委 比 0.00%
- 总股本 2373.86万
- 历史最高 1.90
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.00
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
Entera Bio Ltd. has appointed Riccardo Camisasca, M.D., as its Chief Medical Officer. With over 30 years of experience in global pharmaceutical research and clinical development, Dr. Camisasca previously served as Global Head of Research & Development at Sumitomo Pharma Switzerland. His expertise will strengthen Entera’s clinical execution team and support the upcoming Phase 3 initiation of EB613, an oral anabolic treatment for osteoporosis. Dr. ...
08-18 12:00
Entera Announces Second Quarter 2026 Financial Results and Business Updates
Entera Bio Ltd. reported financial results and updates for Q2 2026, highlighting FDA alignment on a 12-month Phase 3 study for EB613, an oral anabolic tablet for postmenopausal osteoporosis. The company secured $275M in private placement led by BVF Partners to fund EB613's development through NDA submission. EB613's Phase 3 initiation is planned for late 2026, with topline data expected in H2 2028. Additionally, preclinical data for EB612, an ora...
08-07 20:05
Entera Bio prices $275M private placement
Entera Bio (NASDAQ:ENTX) said on Monday it priced an oversubscribed $275M private placement led by existing investor BVF Partners, with participation from several healthcare-focused institutional inve...
07-27 20:59
Entera Bio Enters Into Securities Purchase Agreement For Oversubscribed Private Placement Financing, Expected To Result In Aggregate Gross Proceeds Of ~$275M
Expected gross proceeds are anticipated to extend the Company's cash runway into 2030 and fully support Phase 3 registrational studies for EB613, the first oral PTH(1-34) peptide tablet in development for the treatment of osteoporosis TEL AVIV, July 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASD...
07-27 20:33
Reported Earlier: Entera Bio Receives FDA's Positive Feedback For Its Phase 3 Registrational Protocol For EB613 Tablet In Development To Treat Osteoporosis
Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that it has received positive feedback from the U.S. Food and Drug Administration (FDA) on its Phase 3 registrational protocol for EB613 (oral PTH(1-34), teriparatide), the first...
06-23 00:32
Entera Bio Presents Oral Presentation Titled Transforming Anabolic Treatments For Osteoporosis: Reports Phase 1 Data Showing Single-Tablet EB613 Matches Forteo PK/PD Profile
Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today reported comparative Phase 1 data evaluating single-tablet and multi-tablet oral EB613 with Forteo® (teriparatide SC injection, Eli Lilly). The oral presentation "Transforming Anabolic Trea...
06-15 20:50
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
Entera Bio Ltd. reported Q1 2026 financial results and business updates, highlighting progress in its oral peptide therapeutics pipeline. Key developments include the submission of a streamlined Phase 3 protocol for EB613, an oral anabolic tablet for postmenopausal osteoporosis, and expanded collaboration with OPKO for EB612, an oral long-acting PTH tablet for hypoparathyroidism. Additionally, data for EB618, an oral dual GLP-1/glucagon tablet fo...
05-08 20:05
Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners
MIAMI, April 6, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A. advised Israel-based Entera Bio Ltd. (Nasdaq: ENTX), a clinical-stage biotechnology company focused on the develo...
04-07 01:50
Phreesia, Progress Software And 3 Stocks To Watch Heading Into Monday
U.S. stock futures up, focus on quarterly earnings of Americas Gold and Silver, ARKO Petroleum, Entera Bio, Phreesia, and Progress Software.
03-30 15:29
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
Entera Bio Ltd., a leader in oral peptide development, reported financial and business updates for 2025, highlighting progress in its pipeline, including EB613 for osteoporosis, EB612 for hypoparathyroidism, and EB618 for metabolic syndromes. FDA alignment on BMD as a primary endpoint for EB613 was achieved, with Phase 3 plans advancing. The company also expanded collaborations with OPKO Health and reported cash reserves of $14.9 million, despite...
03-27 20:05
